HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognostic impact of FDG-PET in surgically treated pathological stage I lung adenocarcinoma.

AbstractPURPOSE:
This retrospective study evaluated whether the maximum standardized uptake value (SUVmax) on 18F-deoxyglucose (FDG)-positron emission tomography (PET) could be used to predict the prognosis of patients with pathological stage I adenocarcinoma.
METHODS:
We analyzed 138 consecutive patients with pathological stage IA or IB lung adenocarcinoma except pure bronchioloalveolar carcinoma (BAC) who underwent preoperative FDG-PET imaging and curative resection from January 2005 to October 2010. We analyzed associations between disease-free survival (DFS) and clinicopathological factors.
RESULTS:
The 5-year DFS rate was 77.7%. Twenty two patients (15.9%) developed recurrence after surgery. Multivariate analysis identified SUVmax and lymphovascular (ly) involvement as the independent prognostic factors for recurrence (p = 0.0255 and p = 0.0333, respectively). We divided the patients into groups according to SUVmax and ly involvement. The 5-year DFS rate was 97.0% in patients with SUVmax ≤2.5 and without ly involvement, 100% with both SUVmax ≤2.5 and ly involvement, 70.2% with SUVmax >2.5 and without ly involvement, and 53.1% with both SUVmax >2.5 and ly involvement.
CONCLUSIONS:
The results of this study suggest that SUVmax and ly involvement could be used to predict the prognosis of patients with pathological stage I adenocarcinoma. The combination of these prognostic factors could also identify high risk groups of recurrence.
AuthorsMitsunori Higuchi, Takeo Hasegawa, Jun Osugi, Hiroyuki Suzuki, Mitsukazu Gotoh
JournalAnnals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia (Ann Thorac Cardiovasc Surg) Vol. 20 Issue 3 Pg. 185-91 ( 2014) ISSN: 2186-1005 [Electronic] Japan
PMID23603641 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
Topics
  • Adenocarcinoma (diagnostic imaging, pathology, surgery)
  • Adenocarcinoma of Lung
  • Aged
  • Disease-Free Survival
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Kaplan-Meier Estimate
  • Lung Neoplasms (diagnostic imaging, pathology, surgery)
  • Lymphatic Vessels (diagnostic imaging, pathology)
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Pneumonectomy
  • Positron-Emission Tomography
  • Predictive Value of Tests
  • Proportional Hazards Models
  • Radiopharmaceuticals
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: